West Pharmaceutical Services holds the cleaner structural position, with profitability as the main driver and growth adding further support. Eurofins Scientific SE still leads on valuation and stability, which keeps the comparison from looking entirely one-sided. On the market side, West Pharmaceutical Services is in better shape — its trend is intact while Eurofins Scientific SE's trend has broken down. That puts structure and market broadly in agreement — West Pharmaceutical Services's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (ERF.PA: STOXX 600, WST: Russell 1000).
The clearest separation starts in profitability, with growth adding a second layer of support.
These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.
This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.
Most of the shared profile comes through revenue growth trajectory and capital structure.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
West Pharmaceutical Services, Inc. is cheaper, but Eurofins Scientific SE is still stronger.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where ERF.PA and WST each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The profitability lead is mainly driven by a 8.4-point operating margin advantage.
Stability still leans toward Eurofins Scientific SE, so the lead is real without reading as one-way.
Profitability is the clearest driver of the lead, with growth adding further support — though valuation still provides a real counterweight.
Break down the ERF.PA vs WST comparison across all dimensions with the full interactive tool.
Explore how ERF.PA and WST each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.